# A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00880217** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 430 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine 80 mg/d
- **DRUG:** Placebo
- **DRUG:** OROS methylphenidate HCl 54 mg/d
- **DRUG:** JNJ-31001074 3 mg/d
- **DRUG:** JNJ-31001074 1 mg/d
- **DRUG:** JNJ-31001074 10 mg/d

## Key facts

- **NCT ID:** NCT00880217
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880217, "A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00880217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*